93 related articles for article (PubMed ID: 20644482)
1. Bladder cancer in patients after organ transplantation.
Wallerand H; Ravaud A; Ferrière JM
Curr Opin Urol; 2010 Sep; 20(5):432-6. PubMed ID: 20644482
[TBL] [Abstract][Full Text] [Related]
2. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
Rostaing L; Kamar N
J Nephrol; 2010; 23(2):133-42. PubMed ID: 20155724
[TBL] [Abstract][Full Text] [Related]
3. mTOR inhibition: the learning curve in kidney transplantation.
Weir MR; Diekmann F; Flechner SM; Lebranchu Y; Mandelbrot DA; Oberbauer R; Kahan BD
Transpl Int; 2010 May; 23(5):447-60. PubMed ID: 20136784
[TBL] [Abstract][Full Text] [Related]
4. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
Valantine H
J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
[TBL] [Abstract][Full Text] [Related]
5. [The use of mTOR inhibitors in kidney transplantation: who are the best patients and how should these inhibitors be used?].
Büchler M
Nephrol Ther; 2009 Dec; 5 Suppl 6():S390-4. PubMed ID: 20129451
[TBL] [Abstract][Full Text] [Related]
6. The impact of mTOR inhibitors on the development of malignancy.
Geissler EK
Transplant Proc; 2008 Dec; 40(10 Suppl):S32-5. PubMed ID: 19100904
[TBL] [Abstract][Full Text] [Related]
7. [Antitumoral effect of proliferation signal inhibitors].
Dumortier J
Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S263-7. PubMed ID: 20004333
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus in renal transplant recipients with tuberous sclerosis complex: clinical effectiveness and implications for innate immunity.
Haidinger M; Hecking M; Weichhart T; Poglitsch M; Enkner W; Vonbank K; Prayer D; Geusau A; Oberbauer R; Zlabinger GJ; Soleiman A; Hörl WH; Säemann MD
Transpl Int; 2010 Aug; 23(8):777-85. PubMed ID: 20070623
[TBL] [Abstract][Full Text] [Related]
9. Renal transplant recipients and patients with end stage renal disease present with more advanced bladder cancer.
Ehdaie B; Stukenborg GJ; Theodorescu D
J Urol; 2009 Oct; 182(4):1482-7. PubMed ID: 19683766
[TBL] [Abstract][Full Text] [Related]
10. Renal transplantation in cyclosporine-treated recipients at the Singapore General Hospital.
Vathsala A; Woo KT
Clin Transpl; 1999; ():189-97. PubMed ID: 11038637
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy of hepatocellular cancer.
Wysocki PJ
Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
[TBL] [Abstract][Full Text] [Related]
12. Urothelial carcinoma in kidney transplant recipients: conversion from calcineurin inhibitor to proliferation signal inhibitor?
Chung SD; Lai MK; Wang SM; Liao CH; Yu HJ; Chueh SC
Am J Kidney Dis; 2008 Sep; 52(3):630; author reply 631. PubMed ID: 18725025
[No Abstract] [Full Text] [Related]
13. Harnessing regulatory T cells for transplant tolerance in the clinic through mTOR inhibition: myth or reality?
Zuber J; Hermine O; Chatenoud L; Legendre C
Curr Opin Organ Transplant; 2011 Dec; 16(6):606-13. PubMed ID: 21971509
[TBL] [Abstract][Full Text] [Related]
14. Clinical course of a renal transplant recipient with malignant fibrous histiocytoma: a case report.
Ghods AJ; Nasrollahzadeh D; Asgari M; Fazel I
Transplant Proc; 2004; 36(1):166-7. PubMed ID: 15013335
[TBL] [Abstract][Full Text] [Related]
15. Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation.
Mártinez JM; Pulido LB; Bellido CB; Usero DD; Aguilar LT; Moreno JL; Artacho GS; Díez-Canedo JS; Gómez LM; Bravo MA
Transplant Proc; 2010 Mar; 42(2):641-3. PubMed ID: 20304212
[TBL] [Abstract][Full Text] [Related]
16. Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics.
Dai B; Kong YY; Ye DW; Ma CG; Zhou X; Yao XD
BJU Int; 2009 Oct; 104(7):1009-16. PubMed ID: 19389013
[TBL] [Abstract][Full Text] [Related]
17. Treatment and outcome of invasive bladder cancer in patients after renal transplantation.
Master VA; Meng MV; Grossfeld GD; Koppie TM; Hirose R; Carroll PR
J Urol; 2004 Mar; 171(3):1085-8. PubMed ID: 14767276
[TBL] [Abstract][Full Text] [Related]
18. Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance.
Campistol JM; Albanell J; Arns W; Boletis I; Dantal J; de Fijter JW; Mortensen SA; Neumayer HH; Øyen O; Pascual J; Pohanka E; Schena FP; Serón D; Sparacino V; Chapman JR
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i36-41. PubMed ID: 17456617
[TBL] [Abstract][Full Text] [Related]
19. Urological malignancy as a complication of renal transplantation: a report of twelve clinical cases.
Zhou M; Zhu Y; Wang L; Wang Y; Fu S; Min Z
Clin Transpl; 2006; ():395-8. PubMed ID: 18365395
[TBL] [Abstract][Full Text] [Related]
20. [Pro and anti-neoplastic effects of immunosuppressive drug in renal transplantation].
Infante B; Stallone G; Schena A; Maiorano A; Gesualdo L; Schena FP; Grandaliano G
G Ital Nefrol; 2006; 23(4):389-95. PubMed ID: 17063439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]